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Abstract
Objective
We sought to assess whether genetic risk factors for atrial ﬁbrillation (AF) can explain car-
dioembolic stroke risk.
Methods
We evaluated genetic correlations between a previous genetic study of AF and AF in the
presence of cardioembolic stroke using genome-wide genotypes from the Stroke Genetics
Network (N = 3,190 AF cases, 3,000 cardioembolic stroke cases, and 28,026 referents). We
tested whether a previously validated AF polygenic risk score (PRS) associated with car-
dioembolic and other stroke subtypes after accounting for AF clinical risk factors.
Results
We observed a strong correlation between previously reported genetic risk for AF, AF in the
presence of stroke, and cardioembolic stroke (Pearson r = 0.77 and 0.76, respectively, across
SNPs with p < 4.4 × 10−4 in the previous AFmeta-analysis). An AF PRS, adjusted for clinical AF
risk factors, was associated with cardioembolic stroke (odds ratio [OR] per SD = 1.40, p = 1.45
× 10−48), explaining ;20% of the heritable component of cardioembolic stroke risk. The AF
PRS was also associated with stroke of undetermined cause (OR per SD = 1.07, p = 0.004), but
no other primary stroke subtypes (all p > 0.1).
Conclusions
Genetic risk of AF is associated with cardioembolic stroke, independent of clinical risk factors.
Studies are warranted to determine whether AF genetic risk can serve as a biomarker for strokes
caused by AF.
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Atrial ﬁbrillation (AF) aﬀects nearly 34 million individuals
worldwide1 and is associated with a ﬁvefold increased risk of
ischemic stroke,2 a leading cause of death and disability.3,4 AF
promotes blood clot formation in the heart, which can emb-
olize distally, and is a leading cause of cardioembolism. Sec-
ondary prevention of cardioembolic stroke is directed at
identifying AF as a potential cause and initiating anti-
coagulation to prevent recurrences. Yet, AF can remain occult
even after extensive workup owing to the paroxysmal nature
and fact that it can be asymptomatic. Because both AF and
stroke are heritable, and because there is a compelling clinical
need to determine whether stroke survivors have AF as an
underlying cause, we sought to determine whether genetic
risk of cardioembolic stroke can be approximated by mea-
suring genetic susceptibility to AF.
Recent genome-wide association studies (GWAS) have
demonstrated that both AF5 and ischemic stroke6,7 are
complex disorders with polygenic architectures. The top loci
for cardioembolic stroke, on chromosome 4q25 upstream of
PITX2 and on 16q22 near ZFHX3, are both leading risk loci
for AF.8–10 Despite overlap in top risk loci, the genetic sus-
ceptibility to both AF and cardioembolic stroke is likely to
involve the aggregate contributions of hundreds or thousands
of loci, consistent with other polygenic conditions.11
To understand whether genetic risk of AF is an important and
potentially useful determinant of overall cardioembolic stroke
risk, we analyzed 13,390 ischemic stroke cases and 28,026
referents from theNINDS-Stroke Genetics Network (SiGN)12
with genome-wide genotyping data. First, we assessed whether
patients with stroke with AF have a genetic predisposition to
arrhythmia, leveraging additional GWAS data from the AF
Genetics (AFGen) Consortium. Second, we compared genetic
risk factors for AF and stroke to ascertain the extent to which
heritable risk of cardioembolic stroke is explained by genetic
risk factors for AF.
Methods
The Stroke Genetics Network
The SiGN was established with the aim of performing the
largest genome-wide association study (GWAS) of ischemic
stroke to date. The study design has been previously de-
scribed12 (e-Methods). Brieﬂy, subjects in SiGNwere classiﬁed
into stroke subtypes using the Causative Classiﬁcation System
(CCS), which subtypes cases through an automated, web-
based system that accounts for clinical data, test results, and
imaging information.13,14 Within the CCS, there are 2
subcategories: CCS causative, which does not allow for com-
peting subtypes in a single sample, and CCS phenotypic, which
does. In addition, ;74% of samples were subtyped using the
Trial of ORG 10172 in Acute Stroke Treatment (TOAST)
subtyping system.15 After quality control, the SiGN data set
comprised 16,851 ischemic stroke cases and 32,473 stroke-free
controls (e-Methods and table e-1, links.lww.com/NXG/
A123). In this study, we analyze only the European- and
African-ancestry samples (13,390 cases and 28,026 controls).
Standard protocol approvals, registrations,
and patient consents
All cohorts included in the SiGN data set received approval
from the cohort-speciﬁc ethical standards committee. Cohorts
received written informed consent from all patients or guard-
ians of patients for participation in the study, where applicable.
Details on sample collection have been previously described.12
Identifying AF cases and controls
We deﬁned AF in SiGN on the basis of 5 variables available in
the CCS phenotyping system: (1) AF, (2) paroxysmal AF, (3)
atrial ﬂutter, (4) sick sinus syndrome, and (5) atrial thrombus.
This deﬁnition yielded 3,190 AF cases for analysis. We also
deﬁned a strict case set based on “AF” only (N = 1,751 cases)
for sensitivity analyses (e-Methods and ﬁgure e-1, links.lww.
com/NXG/A123).
From the 28,026 controls, we established a set of 3,861
control individuals in whom AF was indicated as not present.
For the remaining subjects, we assumed that individuals did
not have AF because AF status for most control samples in
SiGN is unknown.
Genome-wide association testing of ischemic
stroke subtypes and AF in SiGN
We merged genotype dosages together and kept single nucle-
otide polymorphisms (SNPs) with imputation quality >0.8 and
minor allele frequency (MAF) >1% (e-Methods, links.lww.
com/NXG/A123). We performed association testing using
a linear mixed model (LMM) implemented in BOLT-LMM.16
We adjusted the model for the top 10 principal components
(PCs) and sex, in addition to the genetic relationship matrix
(GRM; e-Methods).16We performedGWAS inAF and each of
the stroke subtypes available in SiGN. Results were unadjusted
for age because adjusting for age in the AF GWAS gave results
highly concordant with age-unadjusted results (e-Results).
Heritability calculations
We calculated additive SNP-based heritability estimates for
ischemic stroke, stroke subtypes, and AF using restricted
Glossary
AF = atrial ﬁbrillation;AFGen = AFGenetics;CCS =Causative Classiﬁcation System;CI = conﬁdence interval;GRM = genetic
relationship matrix;GWAS = genome-wide association studies;MAF =minor allele frequency;OR = odds ratio; PC = principal
component; PRS = polygenic risk score; SiGN = Stroke Genetics Network.
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maximum (REML) likelihood implemented in BOLT-REML
(e-Methods, links.lww.com/NXG/A123).16
Genetic correlation between AF and ischemic
stroke subtypes
We used summary-level data from a previous AFGen Con-
sortium meta-analysis of AF5 to calculate a z-score for each
SNP in that GWAS. In addition, we calculated a z-score for
each SNP from our SiGN GWAS of each stroke subtype and
AF. As a null comparator, we downloaded SNP z-scores from
a GWAS of educational attainment17 available through
LDHub (ldsc.broadinstitute.org/, accessed November 1,
2017). We calculated Pearson r between z-scores from 2 traits
to evaluate correlation (e-Methods and ﬁgure e-2, links.lww.
com/NXG/A123).
Constructing an AF polygenic risk score (PRS)
To construct an AF PRS, we used SNPs from a previously
derived AF PRS (e-Methods, links.lww.com/NXG/A123).18
Brieﬂy, the PRSwas derived from an AFGWAS of 17,931 cases
and 115,142 controls.5 This PRS comprised 1,168 SNPs with p
< 1 × 10−4 and LD pruned at an r2 threshold of 0.5.18 Of these
1,168 SNPs, we identiﬁed 934 SNPs in the SiGN data set with
imputation info >0.8 and MAF >1%. We used these 934 SNPs
to construct the AF PRS in the SiGNdata set. Additional details
on the PRS construction can be found in the e-Methods.
Testing an AF PRS in ischemic stroke subtypes
We tested for association between the AF PRS and stroke
subtypes using logistic regression (e-Methods, links.lww.
com/NXG/A123). We included sex and the top 10 PCs as
additional covariates. We optionally adjusted the association
tests for age, diabetes mellitus, cardiovascular disease, smok-
ing status (current smoker, former smoker, or never smoked),
and hypertension.
We calculated the variance explained by the AF PRS in car-
dioembolic stroke by constructing a model in BOLT-REML
that consisted of: (1) a variance component made up of SNPs
for the GRM and (2) a variance component made up of SNPs
from the PRS (e-Methods, links.lww.com/NXG/A123).
Data availability
Code, supporting data, and downloadable supplemental tables
are available here: github.com/UMCUGenetics/Aﬁb-Stroke-
Overlap. The e-data (links.lww.com/NXG/A123) contain ad-
ditional information regarding data access, methods, and links
to summary-level data.
Results
We began by testing our ability to rediscover known AF ge-
netic associations in the SiGN data set, assembled to study the
genetics of ischemic stroke. We ran a genome-wide associa-
tion study (GWAS) in SiGN using 3,190 cases, with AF or
paroxysmal AF, as well as other diagnoses suggestive of un-
derlying AF19,20 (e-Methods, table 1 and table e-1, links.lww.
com/NXG/A123), and 28,026 controls (ﬁgure e-1). We
found the top associated SNPs to be highly concordant with
a previous GWAS of AF performed by the AFGen Consor-
tium (table e-2). Adjusting the GWAS for age did not sub-
stantially change our ﬁndings (r = 0.83 between SNP eﬀects
from the age-unadjusted and age-adjusted GWAS).
Table 1 AF and stroke cases in SiGN
Phenotype Total
Ischemic stroke subtype
Primary subtypes Undetermined subtypes
Cardioembolic
Large artery
atherosclerosis
Small artery
occlusion
Incomplete/
unclassified
Cryptogenic/
cardioembolic
minor
AF diagnosis
AF 1,751 1,495 63 32 151 0
Paroxysmal AF 1,315 1,088 52 23 138 0
Left atrial
thrombus
48 37 3 3 4 0
Sick sinus
syndrome
79 65 5 3 4 0
Atrial flutter 106 90 4 2 10 0
Total AF cases 3,190 2,684 123 61 298 0
No AF — 316 2,262 2,201 1,982 2,294
Abbreviations: AF = atrial fibrillation; SiGN = Stroke Genetics Network.
Of the 13,390 stroke cases available in the SiGN data set, a total of 3,190 cases had AF or other suggestive diagnoses. Although most of these cases were
subtyped as having a cardioembolic stroke, a fraction was distributed among the other stroke subtypes. Samples can appear more than once per row (i.e.,
have more than 1 AF diagnosis), but totals represent the number of unique AF samples in each stroke subtype. There are no subjects with AF or equivalent
subtyped as “cryptogenic/cardioembolic minor” because such a diagnosis would remove them from this category.
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By extending our analysis beyond these top associations, we
next assessed whether patients with stroke with AF have
a similar overall genetic predisposition to the arrhythmia as
seen in the independent AFGen GWAS. In addition, we
assessed the overlap between genetic predisposition to AF
and each stroke subtype, allowing for the known phenotypic
concordance between cardioembolic stroke and AF (89.5% of
cardioembolic stroke cases in SiGN also have AF, table e-1,
links.lww.com/NXG/A123). We performed a series of
GWAS in the SiGN data for AF and each of the stroke sub-
types using BOLT-LMM16 (e-Methods) and calculated the
z-score (beta/standard error) of each SNP in each phenotype.
We then used summary-level results available from the pre-
vious (independent) GWAS of AF5 (from AFGen) and cal-
culated the z-score for each SNP in that data set.
By measuring Pearson correlation (r) between AFGen z-scores
and z-scores from the AF GWAS in SiGN, we found only
a modest correlation (r = 0.07 across ;7.8M SNPs, ﬁgure 1,
A and D). However, when we iteratively subsetted the AFGen
GWAS results by the (absolute values of) z-scores of the SNPs,
we found that correlationwith the AFGWAS in SiGN increased
as the z-score threshold became more stringent. For example,
for those;4.5M SNPs with |z| > 1 in AFGen, correlation with
AF SNPs in SiGN was 0.12; for those;1.9M SNPs with |z| >
3.5 in AFGen, correlation with the SiGNAFGWAS rose to 0.77
(ﬁgure 1, A and D, and table e-3). These correlations, calculated
to include even modestly associated SNPs, indicate that AF in
AFGen and AF in stroke (SiGN) share a large proportion of
genetic risk factors. Removing ±2 Mb around the PITX2 and
ZFHX3 loci only modestly aﬀected the correlation between
AFGen and AF in SiGN (r = 0.63 for SNPs with |z| > 3.5; ﬁgure
e-3, links.lww.com/NXG/A123 and table e-3). Correlations
between AFGen and cardioembolic stroke in SiGN were un-
surprisingly highly similar to that of the results with AF in SiGN
(r = 0.77 for AFGen SNPs with |z| > 3.5) likely because of the
high concordance between the AF and cardioembolic stroke
phenotypes (ﬁgure 1, B and E and ﬁgure e-3).
Figure 1 Genetic correlation between atrial fibrillation (AF) in the AF Genetics (AFGen) Consortium meta-analysis and AF
and ischemic stroke subtypes analyzed in SiGN
Pearson r correlation between SNP z-scores in the AFGenGWAS of AF and in GWAS of selected traits performed in the SiGN data. (A) GWAS of AF in AFGen and
in SiGN correlate with increasing strength as SNP z-scores in AFGen increase. Correlation with educational attainment (performed separately, shown here as
a null comparator) remains approximately zero across all z-score thresholds. (B) SNP effects in AFGen also correlate strongly with cardioembolic stroke in
SiGN, but not with the other primary stroke subtypes. (C) Undetermined subtypes of stroke also showmodest correlationwith the genetic architecture of AF in
AFGen. Panels (D–F) show genome-wide z-score distributions underlying correlations. Shading of the hexagons indicates the density of the data at that point,
where darker shading indicates a higher density of SNPs. GWAS = genome-wide association studies.
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Continuing this analysis across the other stroke subtypes
(large artery atherosclerosis, small artery occlusion, and un-
determined stroke; ﬁgure 1, B, C, E, F), we found near-zero
correlation between AFGen and either large artery athero-
sclerosis or small artery occlusion (ﬁgure 1, B and E), in-
dicating no genetic overlap between the phenotypes.
However, the correlation between AF and the undetermined
stroke subtypes (a highly heterogeneous subset of cases21,22
that cannot be classiﬁed with standard subtyping systems13,15)
increased steadily as we partitioned the AFGen data by z-score
(all undetermined vs AFGen r = 0.04 for AFGen SNPs with |
z| > 1 and r = 0.16 for AFGen SNPs with |z| > 3.5; ﬁgure 1, C
and F, and table e-3, links.lww.com/NXG/A123), indicating
that genome wide, there is residual genetic correlation be-
tween AF and the undetermined stroke categories, some of
which could represent causal AF stroke mechanisms in that
subgroup. As an additional null comparator, we performed
correlations between the AFGen results with z-scores derived
from the latest GWAS of educational attainment17 and found
that correlation remained at approximately zero regardless of
the z-score threshold used (ﬁgure 1, A and D, and table e-3).
To further understand the overlap between genetic risk factors
for AF and cardioembolic stroke and to evaluate the degree to
which cardioembolic stroke comprised risk factors beyond
those for AF, we performed a restricted maximum likelihood
analysis implemented in BOLT-REML16 to estimate SNP-
based heritability of AF and cardioembolic stroke. Using
phenotypes derived from the CCS subtyping algorithm23
(e-Methods, links.lww.com/NXG/A123), we estimated heri-
tability of AF and cardioembolic stroke at 20.0% and 19.5%,
respectively. These estimates are consistent with previous
estimates in larger samples (ﬁgure e-4),24,25 and the similar
heritabilities suggest that cardioembolic stroke does not have
a substantial heritable component beyond the primary AF risk
factor. For comparison, we calculated heritability in the other
stroke subtypes15 and found estimates to be similarly modest
(range: 15.5%–23.0%; ﬁgures e4-e6 and table e-4).
Up to this point, our results indicated that AF in ischemic stroke
is genetically similar to that discovered in previous genetic studies
of AF alone and that the bulk of the genetic risk of cardioembolic
stroke seems attributable to AF genetic risk factors. Next, we
sought to explicitly test what proportion of cardioembolic stroke
risk could be explained by AF loci, independent of known clinical
risk factors for AF. First, we identiﬁed SNPs from an AF PRS
independently derived from the AFGen GWAS5 (e-Methods,
links.lww.com/NXG/A123). Of the 1,168 SNPs used to gen-
erate this pre-established PRS, we identiﬁed 934 in the SiGN
data set with imputation quality >0.8 and MAF >1%. We com-
puted the PRS per individual (e-Methods), weighting the im-
puted dosage of each risk allele by the eﬀect of the SNP (i.e., the
beta coeﬃcient) as reported in AFGen.5
We tested the association of the AF PRS with cardioembolic
stroke, using a logistic regression and adjusting for the top 10
PCs and sex (e-Methods, links.lww.com/NXG/A123). As
expected from our earlier results, we found the PRS to be
strongly associated with cardioembolic stroke (odds ratio
[OR] per 1 SD of the PRS = 1.93 (95% conﬁdence interval
[CI]: 1.34–1.44), p = 1.01 × 10−65; ﬁgure 2A and table e-5),
conﬁrming the high genetic concordance of these phenotypes
across SNPs that, individually, confer only a modest average
association with AF. Next, we adjusted the association
model for clinical covariates associated with AF including
age, diabetes mellitus, cardiovascular disease, smoking, and
Figure 2 Association of atrial fibrillation (AF) polygenic risk score in ischemic stroke subtypes
We constructed an independent polygenic risk score (PRS) from AF-associated SNPs identified in the AFGen GWAS and tested associations between this PRS
and ischemic stroke subtypes using (A) all available referents (N = 28,026) and (B) referents without AF (N = 3,861). The PRS strongly associated with
cardioembolic stroke in both sets of samples. In the AF-free set of controls (panel B), we observed association of the PRS (p < 5 × 10−3, after adjusting for 5
subtypes and 2 sets of referents; indicated by the dashed dark blue line) with incomplete/unclassified stroke as well. GWAS = genome-wide association
studies; PRS = polygenic risk score.
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hypertension.26 Using a (smaller) set of cases and controls
with complete clinical risk factor information, we found that
inclusion of these clinical risk factors in the model only
modestly reduced the PRS signal in cardioembolic stroke (OR
per 1 SD = 1.40 [95% CI: 1.34–1.47], p = 1.45 × 10−48; tables
e5-e7, links.lww.com/NXG/A123). These results indicate
a strong relationship between AFGen risk factors and car-
dioembolic stroke risk, independent of the clinical factors that
associate with AF. Expanding the set of SNPs used to con-
struct the PRS to the original 934 SNPs ±25 kb, ±50 kb, and
±100 kb (e-Methods) revealed a persistently strong, though
somewhat attenuated, association between the PRS and car-
dioembolic stroke (PRS including SNPs within 100 kb, p =
4.47 × 10−44, table e-6). None of the other stroke subtypes
were signiﬁcantly associated with the AF PRS (all p > 0.013,
ﬁgure 2A and ﬁgure e-7).
Because AF status was missing for most controls in the SiGN
data set, we performed sensitivity analyses using only the 3,861
controls conﬁrmed as having no AF. Although reducing the
set of controls to this reﬁned group did not substantially change
the results for the primary stroke subtypes, we found that
the AF PRS was modestly associated (p < 5 × 10−3, after
adjusting for 5 subtypes and 2 control groups) with the overall
undetermined subtype (OR per 1 SD = 1.07 [95% CI:
1.02–1.13], p = 4.15 × 10−3) (ﬁgure 2B and table e-5, links.lww.
com/NXG/A123). Further examination of the 2 mutually ex-
clusive subgroups of the undetermined group revealed that the
PRS associated signiﬁcantly with the incomplete/unclassiﬁed
categorization (OR per 1 SD = 1.09 [95% CI: 1.03–1.16],
p = 3.17 × 10−3) (ﬁgure 2B) but not with cryptogenic/
cardioembolic minor (OR per 1 SD = 1.06 [95% CI:
1.00–1.13], p = 5.10 × 10−2). Correcting for clinical cova-
riates only modestly changed the signal in the incomplete/
unclassiﬁed phenotype (p = 9.7 × 10−3, ﬁgure 2), supporting
the robustness of the observed association, independent of
clinical risk factors.
Last, we created a model in BOLT-LMM, ﬁtting 2 genetic
variance components: 1 component including SNPs for the
GRM and the second component including the original PRS
SNPs from the AF PRS (including ±100 kb around these SNPs
to include a suﬃcient number of markers to estimate the var-
iance explained) (table e-8). We found that the SNPs from the
AF PRS explained 4.1% of the total (20.0%) heritability in AF.
In evaluating the variance explained in cardioembolic stroke, we
found a nearly identical result: the component representing the
AF risk score explained 4.5% (SE = 1.00%) of the total 19.5%
genetic heritability in cardioembolic stroke. Thus, AF genetic
risk accounts for 23.1%, or approximately one-ﬁfth, of the total
heritability of cardioembolic stroke.
Discussion
Our results suggest that individuals with cardioembolic
strokes have an enrichment for AF genetic risk, despite the
fact that cardioembolic stroke often aﬀects older adults with
multiple clinical comorbidities27 that could increase risk of AF
because of nongenetic factors. The fact that cardioembolic
stroke and AF share a highly similar genetic architecture
extends our understanding of the morbid consequences of
heritable forms of arrhythmia. Furthermore, the observation
that AF genetic risk was only associated with cardioembolic
stroke, and (consistently) lacked association in large artery
atherosclerosis or small artery occlusion,28 increases the pos-
sibility that AF genetic risk may be informative in the man-
agement of ischemic stroke survivors in whom the mechanism
may be unclear.
The use of PRSs for complex traits has proved an eﬃcient
means of understanding how genetic predisposition to diseases
can overlap. Given the onslaught of genotyping data available
for common diseases, PRSs can now be used to stratify patients
by risk (e.g., in breast cancer29,30) or predict outcome (e.g., in
neuropsychiatric disease29). More recently, PRSs have been
used to identify individuals in the general population with
a four-fold risk of coronary disease,31 proposed for inclusion in
clinical workups of individuals with early-onset coronary artery
disease,32 and used to identify patients for whom lifestyle
changes or statin intervention would be beneﬁcial.33,34 Al-
though previous work has also shown an association between
an AF PRS and cardioembolic stroke,28 we have extended this
work to formally quantify the extent to which an AF PRS
captures genetic risk of cardioembolic stroke. These ﬁndings
lay the groundwork for future work that can potentially lever-
age this overlap to develop AF PRSs that could be used to
predict individuals at highest risk of cardioembolic stroke (to
improve diagnostic resource allocation) or help distinguish
between clinical subtypes of stroke.
Although our analysis was aimed at understanding the genetic
overlap between cardioembolic stroke and AF, we addition-
ally observed genetic correlation between AF and un-
determined stroke, a ﬁnding not observed in a previous
investigation of AF PRS in ischemic stroke subtypes, albeit in
a smaller sample.28 Perhaps contrary to expectation, we spe-
ciﬁcally found the AF PRS to bemore strongly associated with
the subset of etiology-undetermined strokes with an in-
complete clinical evaluation, as opposed to those with cryp-
togenic stroke of a presumed, but not demonstrated, embolic
source. These associations could be due to physician biases
in diagnostic workups, rather than supporting a low preva-
lence of occult AF in presumed embolic strokes of un-
determined source. Identifying patients with stroke with AF is
an important clinical challenge because occult AF is well
known to cause strokes35,36 and because such patients are at
high risk of recurrent stroke, which is preventable with
anticoagulation.37,38 Together, our ﬁndings indicate that AF
genetic risk may augment clinical algorithms to determine
stroke etiology, but will require further study.
The work presented here beneﬁts from a number of
improvements, including increased sample size; analysis of
samples from amulticenter consortium, potentially enhancing
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the generalizability of the ﬁndings; and use of the CCS sub-
typing system, which provides more nuanced phenotyping,
particularly in the cryptogenic subtype. Nevertheless, some
limitations remain. Stroke is a heterogeneous condition that
occurs later in life and has a high lifetime prevalence (>15%39),
features that can reduce statistical power. Furthermore, sample
sizes have lagged behind other GWAS eﬀorts, a challenge fur-
ther compounded by subtyping (nearly one-third of all cases
are categorized as undetermined23). Reduced sample sizes af-
fect power for discovery and make other analytic
approaches—such as standard approaches for measuring trait
correlation16—unfeasible. Also, our sample primarily com-
prised European-ancestry samples, and work in non-
Europeans, particularly in African-ancestry samples where
risk of stroke is double that of European samples, is crucial.
Finally, the current analysis does not analyze rare variations,
which also likely contributes to disease susceptibility.5
We have shown that the cumulative genetic risk of AF in
individuals with a stroke is similar to that reported in a larger
population-based cohort.25 Genome-wide variation related to
AF is substantially associated with cardioembolic stroke risk.
Moreover, AF genetic risk was speciﬁc for cardioembolic
stroke and was not associated with the other primary stroke
subtypes. The observation that AF genetic risk associated with
strokes of undetermined cause supports the notion that un-
detected AF underlies a proportion of stroke risk in these
individuals. Further work will need to incorporate emerging
discoveries of rare genetic variants in AF and explore the
potential of genetic risk tools, including PRSs performed via
clinical-grade genotyping, to assist in the diagnostic workup of
individuals with ischemic stroke.
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